Gilead Sciences Inc at Bank of America Global Healthcare Conference Transcript

May 09, 2023 / 06:20PM GMT
Geoffrey Christopher Meacham - BofA Securities, Research Division - Research Analyst

(technical difficulty) to the morning session of the BofA Healthcare Conference. So my name is Geoff Meacham. I'm the senior biopharma analyst. And we're thrilled today to have Gilead Sciences. And up on stage with me is Andy Dickinson. Andy, welcome.

Andrew D. Dickinson - Gilead Sciences, Inc. - Executive VP & CFO

Thank you. Great to be here. Thanks for having us.

Questions and Answers:

Geoffrey Christopher Meacham - BofA Securities, Research Division - Research Analyst

So Andy, let's kick off with just following first quarter. Give us some perspective on kind of the guidance changes that you guys have made with respect to R&D and kind of what implications that has as kind of the expenses over the course of the year.

Andrew D. Dickinson - Gilead Sciences, Inc. - Executive VP & CFO

Sure. Yes. Maybe I'll start actually just by hitting kind of on the top line first and then
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot